FDA Cites Pharmaceutical Companies for Misleading Drug Advertising

Strategic Insights -

Pharmaceutical companies have been criticized for misleading consumers through the use of inaccurate information, distractions, and unsubstantiated claims in their advertising campaigns. The Food and Drug Administration (FDA) has taken action against several companies, including Amgen, Novartis, Wyeth Pharmaceuticals, and GlaxoSmithKline, for violating the Food, Drug and Cosmetic Act by presenting inaccurate information and unfairly representing the benefits and risks of their products.

Key Takeaways:

  • **Minimizing Risks:** The FDA has cited Amgen for minimizing the risks associated with its psoriasis medication, Enbrel, in a 60-second TV spot. The ad provided risk information through audio while using distracting visuals, which made it difficult for viewers to understand the potential side effects.
  • **Overstating Effectiveness:** Novartis was reprimanded for an ad that claimed its Lamisil prescription-strength toenail fungus treatment was effective for all or most patients, when only 38% of clinical trial participants were cured.
  • **Broadening a Drug's Use:** The FDA accused Wyeth Pharmaceuticals of using a radio ad to broaden the audience for its Effexor XR antidepressant by failing to convey the serious nature of major depressive disorder and to distinguish symptoms of depression from variations of normal daily functioning.
  • **Unsubstantiated Claims:** Hoffman-La Roche received a warning letter for a patient video that contained unsubstantiated claims about the cancer drug Xeloda, including that it didn't make patients feel tired or sick, despite the high incidence of reports that the drug caused such side effects.

Statistics:

  • **38%:** The percentage of patients in clinical trials who were cured using Lamisil, a prescription-strength toenail fungus treatment, despite an ad claiming effectiveness for all or most patients.
  • **10,000** U.S. oncologists: The number of practitioners who received corrective letters from Hoffman-La Roche regarding the unsubstantiated claims made about its Xeloda cancer medication in a patient video.
  • **4 companies:** The number of pharmaceutical companies cited by the FDA for violating the Food, Drug and Cosmetic Act by presenting inaccurate information and unfairly representing the benefits and risks of their products.

Sources:

  • Julie Schmit, The Food, Drug and Cosmetic Act requires that drug promotions present accurate information and fairly represent a drug's benefits and risks
  • FDA citation to Amgen, [02/2023] (Undated)
  • FDA citation to Novartis, [2003]
  • FDA citation to Wyeth Pharmaceuticals, [Undated]
  • FDA citation to GlaxoSmithKline, [2004]
  • FDA warning letter to Hoffman-La Roche, [2003]